Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015

1 December 2011

The acute coronary syndrome (ACS) drug market in Brazil will nearly double from $122 million in 2010 to $229 million in 2015, according to advisory firm Decision Resources new Emerging Markets report, Acute Coronary Syndrome in Brazil.

Growth will be driven by the uptake of novel antithrombotic agents as well as an aging Brazilian population, improved access to medical care and a rising number of higher-income patients driving the demand for more expensive drugs. The launch of several novel premium-priced agents will account for around 22 %of total sales in 2015.

Expansion in private health insurance coverage, increases in disposable income among those without health insurance and the expected increase in government healthcare spending will also contribute to a rise in percutaneous coronary intervention (PCI) procedures between 2010 and 2015, says the report.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK